Helsinki-based Aplagon has secured €7m in financing to advance its therapeutic APAC into Phase 2a clinical trials.
ADVERTISEMENT
ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
Helsinki-based Aplagon has secured €7m in financing to advance its therapeutic APAC into Phase 2a clinical trials.